Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab versus tocilizumab + baricitinib in severe COVID-19
IRCT20151227025726N30Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Mar 2022
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in coronavirus pneumonia comparing Tocilizumab alone with Tocilizumab + baricitinib (2 arms). Primary endpoints: Duration of hospitalization, Duration of hospitalization in the ICU and 5 more. Started Mar 2022; status: completed.
02
Drugs
tocilizumabbaricitinib
03
Conditions
coronavirus pneumonia
Beyond the preview
Go deeper on IRCT20151227025726N30.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20151227025726N30.